Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

3,027

Participants

Timeline

Start Date

October 4, 2010

Primary Completion Date

June 15, 2011

Study Completion Date

June 15, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza vaccine GSK2321138A

intramuscular injections

BIOLOGICAL

FluarixTM

intramuscular injections

BIOLOGICAL

Influenza vaccine GSK2604409A

intramuscular injections

Trial Locations (59)

1113

GSK Investigational Site, Quezon City

1600

GSK Investigational Site, Prague

4114

GSK Investigational Site, Dasmariñas, Cavite

10315

GSK Investigational Site, Berlin

10967

GSK Investigational Site, Berlin

13055

GSK Investigational Site, Berlin

13100

GSK Investigational Site, Aix-en-Provence

13210

GSK Investigational Site, Syracuse

13901

GSK Investigational Site, Binghamton

14901

GSK Investigational Site, Elmira

22307

GSK Investigational Site, Hamburg

24937

GSK Investigational Site, Flensburg

25070

GSK Investigational Site, Odolena Voda

27609

GSK Investigational Site, Raleigh

28002

GSK Investigational Site, Kolín

31600

GSK Investigational Site, Seysses

33432

GSK Investigational Site, Boca Raton

35340

GSK Investigational Site, La Bouëxière

37100

GSK Investigational Site, Tours

37269

GSK Investigational Site, Eschwege

37701

GSK Investigational Site, Jindřichův Hradec

38302

GSK Investigational Site, Wolfenbüttel

40509

GSK Investigational Site, Lexington

42579

GSK Investigational Site, Heiligenhaus

42719

GSK Investigational Site, Solingen

44300

GSK Investigational Site, Nantes

47533

GSK Investigational Site, Kleve-Materborn

47877

GSK Investigational Site, Willich

54270

GSK Investigational Site, Essey-lès-Nancy

54290

GSK Investigational Site, Trier

67205

GSK Investigational Site, Wichita

67207

GSK Investigational Site, Wichita

68134

GSK Investigational Site, Omaha

70006

GSK Investigational Site, Metairie

70469

GSK Investigational Site, Stuttgart

74523

GSK Investigational Site, Schwäbisch Hall

76600

GSK Investigational Site, Le Havre

76904

GSK Investigational Site, San Angelo

77055

GSK Investigational Site, Houston

77694

GSK Investigational Site, Kehl

77955

GSK Investigational Site, Ettenheim

78532

GSK Investigational Site, Tuttlingen

81735

GSK Investigational Site, Munich

82205

GSK Investigational Site, Gilching

83300

GSK Investigational Site, Draguignan

85551

GSK Investigational Site, Kirchheim

86720

GSK Investigational Site, Nördlingen

95816

GSK Investigational Site, Sacramento

97941

GSK Investigational Site, Tauberbischofsheim

99425

GSK Investigational Site, Weimar

02130

GSK Investigational Site, Boston

405 01

GSK Investigational Site, Děčín

396 01

GSK Investigational Site, Humpolec

547 01

GSK Investigational Site, Náchod

532 03

GSK Investigational Site, Pardubice

305 99

GSK Investigational Site, Pilsen

390 02

GSK Investigational Site, Tábor

06300

GSK Investigational Site, Nice

04178

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01196988 - Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children | Biotech Hunter | Biotech Hunter